Clinical Trial

Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy

Name: Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy — clinical trial record (NCT07197112)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: GRIT

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

An open-label, single-arm clinical trial to evaluate the safety and efficacy of gecacitinib tablets in patients with acute graft-versus-host disease (GVHD) who have failed or are intolerant to ruxolitinib-containing second-line therapy.

Trial Details

NCT Number	NCT07197112
Lead Sponsor	Ruijin Hospital
Conditions	Acute Graft Versus Host Disease Grade II-IV, Acute Graft vs Host Disease
Enrollment	15 participants
Start Date	2025-10-01
Primary Completion	2027-02-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-09-29